Furthermore, our drug delivery system utilizes CD11b antibody modification to enhance targeting of macrophages, with the primary goal of promoting uptake by M2 macrophages and inducing their repolarization into the tumor‐suppressive M1 phenotype. The gene discussed is ITGAM; the disease is neoplasm.